Metabolic Disorders
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Fate TherapeuticsProHema-CB Transplant
RegeneronREGN1500
Clinical Trials (2)
Total enrollment: 55 patients across 2 trials
A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders
Start: Jun 2015Est. completion: Feb 2017
Phase 1Terminated
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
Start: Apr 2014Est. completion: Sep 201555 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space